Systematic review and meta-analysis of corticosteroids for the resolution of malignant bowel obstruction in advanced gynaecological and gastrointestinal cancers
Dj. Feuer et Ke. Broadley, Systematic review and meta-analysis of corticosteroids for the resolution of malignant bowel obstruction in advanced gynaecological and gastrointestinal cancers, ANN ONCOL, 10(9), 1999, pp. 1035-1041
Background: The objective was to locate, appraise and summarise evidence fr
om scientific studies on intestinal obstruction due to advanced gynaecologi
cal and gastrointestinal cancers, in order to assess the efficacy of cortic
osteroids.
Materials and methods. Data sources: A comprehensive list of studies was pr
ovided by an extensive search of electronic databases, relevant journals, b
ibliographic databases, conference proceedings, reference lists, the grey l
iterature, personal contact and the world wide web. Data synthesis: Two res
earchers extracted the data independently. A qualitative analysis was perfo
rmed of the dichotomous data of resolution of obstruction and death at one
month. Both fixed and random effect models were used. Number needed to trea
t (with corticosteroids to resolve one episode of bowel obstruction) was de
rived from the odds ratio. Kaplan-Meier survival curves from individual pat
ient data were also analysed. Studies of lower methodological quality were
assessed in a qualitative manner.
Results: There is a trend towards resolution of bowel obstruction using cor
ticosteroids, but this result does not achieve statistical significance. Th
ere is no statistically significant difference in mortality at one month, n
or in the Kaplan-Meier survival curves. Number needed to treat is 6, though
with wide confidence intervals (3-infinity). The results are robust to fix
ed and random effects models and to 'best' and 'worst case' scenarios on th
e data from missing patients. The morbidity associated with corticosteroids
appears to be very low.
Conclusions: The role of corticosteroids needs further elucidation. More pa
tients need to be recruited in order to obtain more precise results. Furthe
r trials should include quality of life measures as primary outcomes as wel
l as most effective type of corticosteroid, dose or dosing regime, route of
administration and morbidity.